Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of “Moderate Buy” by Analysts

Nkarta, Inc. (NASDAQ:NKTX) has earned an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $13.25.

Several brokerages recently issued reports on NKTX. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 target price on shares of Nkarta in a research report on Wednesday, August 13th. Wall Street Zen upgraded Nkarta from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nkarta in a research report on Friday, October 31st. Finally, Stifel Nicolaus decreased their price target on shares of Nkarta from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, November 11th.

Institutional Trading of Nkarta

Hedge funds have recently added to or reduced their stakes in the business. Savant Capital LLC purchased a new stake in shares of Nkarta in the 2nd quarter worth approximately $36,000. SG Americas Securities LLC raised its stake in Nkarta by 35.0% during the third quarter. SG Americas Securities LLC now owns 23,663 shares of the company’s stock valued at $49,000 after buying an additional 6,141 shares during the last quarter. CWM LLC boosted its holdings in Nkarta by 23.4% in the second quarter. CWM LLC now owns 34,758 shares of the company’s stock worth $58,000 after acquiring an additional 6,601 shares in the last quarter. Bailard Inc. purchased a new stake in shares of Nkarta in the third quarter worth $61,000. Finally, Forefront Wealth Partners LLC bought a new position in shares of Nkarta during the third quarter valued at $82,000. 80.54% of the stock is owned by institutional investors.

Nkarta Price Performance

NKTX opened at $1.81 on Tuesday. The company has a fifty day moving average price of $2.08 and a 200-day moving average price of $2.00. Nkarta has a one year low of $1.31 and a one year high of $3.16. The firm has a market capitalization of $128.56 million, a P/E ratio of -1.31 and a beta of 0.80.

Nkarta (NASDAQ:NKTX) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.03. On average, analysts expect that Nkarta will post -1.7 earnings per share for the current year.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.